My Number #1 Biotech Stock

You're receiving this email as part of your subscription to Lou Basenese’s Trend Trader Daily. [Unsubscribe](. [Trend Trader Daily]( My Number #1 Biotech Stock Thursday, November 11, 2021 [Earlier in the week](, I alerted you to the quickening pace of buyouts in the biotech industry. And of course, the triple-digit profit potential. With Big Pharma companies like Pfizer Inc. (PFE) paying more than 200% to snap up compelling biotech companies, we’d be fools not to add several compelling takeover targets to our portfolios. Stat! Here’s the thing, though: I don’t want you to mistakenly believe that the only way to profit in biotech is from takeover announcements. Not hardly! Fact is, I’ve been pounding the table to buy biotech stocks for the better part of two years. And the results have been nothing short of amazing. Let me prove it, and then I’ll share with you my Top Biotech Stock for right now. I’m so bullish on this one that I have $300,000 of my own money in it. And I believe it could double in price in the next few days alone. > ADVERTISEMENT < One Tiny Company Has Big Pharma by the Throat! One $13 per share biotech stock could make an [historic announcement this Saturday, November 13th...]( And when it does, I believe the biggest names in biotech will be scrambling to buy this tiny firm... Handing anyone who snags shares right now (while they're still cheap!) a potential fortune. Specifically, we could seen gains as high as 1,096%. But ONLY if you're "IN" before this [Saturday, November 13th!]( [Click here now to get caught up »]( Up, Up and Away As we all know, the markets change every day, and new investment trends emerge. One of those trends hit unexpectedly at the beginning of 2020… That’s when Covid-19 became a real threat — and for a handful of biotech companies that could provide testing and treatment options, a real opportunity. I spotted this trend early and identified seven small biotech companies that stood to benefit the most. The rest is history… All seven started soaring in price almost immediately: - Within 30 days, readers were locking in gains of 105% in GenMark Diagnostics (GNMK), and 116% in Vaxart (VXRT). - Within 60 days, readers were locking in gains of 243% in Novavax (NVAX). - And within 120 days, readers were locking in gains of 226% in Inovio Pharmaceuticals (INO) and 640% in Altimmune (ALT). And for investors that held onto all their shares of Novavax until my final sell alert… they took home a staggering profit of 949.8% in just 136 days. That’s a ten-bagger in just a few months. And mind you, this wasn’t some fluke related to Covid-19. Over the last twenty years, small biotech stocks have helped me routinely deliver triple-digit profits in rapid succession — including biotechs that were unrelated to Covid. And I don’t expect that trend to end anytime soon. In fact, I’m so bullish on biotech stocks — and so bullish on one company in particular — I’ve made it my single largest investment. I have over $300,000 of my own hard-earned money invested in it. Why so much? Because the company is working on what I believe will prove to be a “Plug & Play” cure for cancer, and then a cure for all manner of autoimmune and infectious diseases, as well. Given its platform technology, and the takeover premiums in the biotech industry right now, I’m projecting this company will soon be worth billions of dollars… starting as soon as this week. I stand to personally make over a million dollars in pure profit on this investment. And I want to make sure you don’t miss out on the opportunity, too. So hurry up and click on the link below to find out all the details. Time is of the essence, as the company is set to report new data this weekend. If you don’t get positioned beforehand, you could regret it. [My Top Biotech Stock to Own Right Now]( Ahead of the tape, [Lou Basenese] Lou Basenese Founder & Chief Investment Strategist Copyright © 2021 Trend Trader Daily, All rights reserved. You signed up on []( Our mailing address is: Trend Trader Daily 301 S. Perimeter Park Dr. Suite 100 Nashville, Tennessee 37211 [Update Subscription Preferences]( | [Unsubscribe from this list]( RISK NOTICE: All investing comes with risk. That includes the investments teased in this letter. You should never invest more than you can afford to lose. Please use this research for the purpose that it's intended — as research only. You should consult a professional financial advisor before ever taking a position in any securities you see herein. SECURITY HOLDING NOTICE: Although we are never compensated from any companies for coverage, you should be aware that Trend Trader Daily, its authors, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. While authors might actively transact in the securities mentioned, they will always have a net position that is consistent with the position set forth in our research reports, letters and updates. DISCLAIMERS: The work included in this communication is based on diverse sources including SEC filings, current events, interviews, corporate press releases, and information published on funding platforms, but the views we express and the conclusions we reach are our own. As such, this content may contain errors, and any investments described in this content should be made only after reviewing the filings and/or financial statements of the company, and only after consulting with your investment advisor. Actual results may differ significantly from the results described herein. Furthermore, nothing published by Trend Trader Daily, Inc should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. Trend Trader Daily is an independent provider of education, information and research on publicly traded companies, and as such, it accepts no direct or indirect compensation from any companies or third parties mentioned in any of our letters, reports or updates.